FDA Follow-On Biologics Guidance Delay Applauded By Senate Health Cmte. Staffer
This article was originally published in The Pink Sheet Daily
Executive Summary
Senate Committee does not believe FDA should develop a guidance that focuses solely on the scientific issues of follow-on biologics and let "the legal chips fall where they may." Congress should "thoroughly" review legal landscape before FDA issues guidance.